A Multi-Center, Randomized, Controlled, Double-Blind, Parallel Group, Phase 2 Clinical Trial To Evaluate the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients with NASH Cirrhosis
Principal Investigator(s)
Email for information
Funded by
Geneva Foundation
Research Start Date
Status
Active
The Overall Study Sponsor has developed to evaluate the safety and efficacy of GR-MD-02 for the treatment of liver fibrosis and resultant portal hypertension in patients with NASH cirrhosis.
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.